EE200200631A - Vesisuspensioonipõhine parenteraalne ravimpreparaat stabiliseeritud pH väärtusega ning L-metioniinikasutamine selle valmistamiseks - Google Patents

Vesisuspensioonipõhine parenteraalne ravimpreparaat stabiliseeritud pH väärtusega ning L-metioniinikasutamine selle valmistamiseks

Info

Publication number
EE200200631A
EE200200631A EEP200200631A EEP200200631A EE200200631A EE 200200631 A EE200200631 A EE 200200631A EE P200200631 A EEP200200631 A EE P200200631A EE P200200631 A EEP200200631 A EE P200200631A EE 200200631 A EE200200631 A EE 200200631A
Authority
EE
Estonia
Prior art keywords
preparation
methionine
stabilized
water
parenteral pharmaceutical
Prior art date
Application number
EEP200200631A
Other languages
English (en)
Inventor
Colombo Giuseppe
Martini Alessandro
E. Fox Lloyd
Original Assignee
Pharmacia Italia S.P.A.
Pharmacia & Upjohn Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Italia S.P.A., Pharmacia & Upjohn Company filed Critical Pharmacia Italia S.P.A.
Publication of EE200200631A publication Critical patent/EE200200631A/et
Publication of EE05376B1 publication Critical patent/EE05376B1/et

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
EEP200200631A 2000-05-15 2001-04-25 Vesisuspensioonip?hineÁparenteraalneÁravimpreparaatÁjaÁsedaÁsisaldavÁviaal EE05376B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/571,395 US6495534B2 (en) 2000-05-15 2000-05-15 Stabilized aqueous suspensions for parenteral use
PCT/EP2001/004643 WO2001087266A1 (en) 2000-05-15 2001-04-25 Stabilized aqueous suspensions for parenteral use

Publications (2)

Publication Number Publication Date
EE200200631A true EE200200631A (et) 2004-04-15
EE05376B1 EE05376B1 (et) 2011-02-15

Family

ID=24283530

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200631A EE05376B1 (et) 2000-05-15 2001-04-25 Vesisuspensioonip?hineÁparenteraalneÁravimpreparaatÁjaÁsedaÁsisaldavÁviaal

Country Status (30)

Country Link
US (3) US6495534B2 (et)
EP (1) EP1282402B1 (et)
JP (1) JP4205341B2 (et)
KR (1) KR100828957B1 (et)
CN (1) CN100473376C (et)
AR (3) AR029924A1 (et)
AT (1) ATE313316T1 (et)
AU (2) AU6737101A (et)
BR (1) BR0110841A (et)
CA (1) CA2409059C (et)
CZ (1) CZ303872B6 (et)
DE (1) DE60116084T2 (et)
DK (1) DK1282402T3 (et)
EA (1) EA007682B1 (et)
EE (1) EE05376B1 (et)
ES (1) ES2254443T3 (et)
HK (1) HK1054194B (et)
HU (1) HU229800B1 (et)
IL (2) IL152537A (et)
IN (1) IN224279B (et)
MX (1) MXPA02011195A (et)
NO (1) NO332215B1 (et)
NZ (1) NZ522324A (et)
PE (1) PE20011322A1 (et)
PL (1) PL203075B1 (et)
SI (1) SI1282402T1 (et)
SK (1) SK287641B6 (et)
TW (1) TWI256310B (et)
WO (1) WO2001087266A1 (et)
ZA (1) ZA200208738B (et)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6495534B2 (en) * 2000-05-15 2002-12-17 Pharmacia & Upjohn Spa Stabilized aqueous suspensions for parenteral use
US7482116B2 (en) 2002-06-07 2009-01-27 Dna Genotek Inc. Compositions and methods for obtaining nucleic acids from sputum
AU2003265511A1 (en) 2002-08-21 2004-03-11 Pharmacia Corporation Injectable pharmaceutical suspension in a two-chamber vial
AU2003290647A1 (en) * 2002-11-08 2004-06-03 Bristol-Myers Squibb Company Pharmaceutical compositions and methods of using taxane derivatives
CN1767815A (zh) * 2003-03-31 2006-05-03 阿尔萨公司 非水单相载体和使用这类载体的制剂
JP5651279B2 (ja) 2003-09-03 2015-01-07 ミスコン トレイディング エス．エー． 子宮内膜症の処置のための方法
US20050171167A1 (en) * 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
US20050106214A1 (en) * 2003-11-14 2005-05-19 Guohua Chen Excipients in drug delivery vehicles
US20060058390A1 (en) * 2004-09-14 2006-03-16 Molecular Therapeutics, Inc. D-methionine formulation with improved biopharmaceutical properties
US20060204588A1 (en) * 2005-03-10 2006-09-14 Elan Pharma International Limited Formulations of a nanoparticulate finasteride, dutasteride or tamsulosin hydrochloride, and mixtures thereof
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
US20070154546A1 (en) * 2005-12-30 2007-07-05 Zhang Jack Y Sustained release pharmaceutical compositions
CA2642577A1 (en) * 2006-02-15 2007-08-23 Tika Lakemedel Ab Methods of manufacturing corticosteroid solutions
TW200806317A (en) * 2006-03-20 2008-02-01 Wyeth Corp Methods for reducing protein aggregation
JP5371180B2 (ja) * 2006-06-15 2013-12-18 日立コンシューマエレクトロニクス株式会社 投写型映像表示装置
US7687516B2 (en) * 2006-09-27 2010-03-30 Eagle Pharmaceuticals, Inc. Alcohol free formulation of argatroban
JP5624766B2 (ja) * 2006-09-27 2014-11-12 イーグル・ファーマシューティカルズ・インコーポレーテッド アルコールを含まないアルガトロバン製剤
US20100076019A1 (en) * 2006-10-11 2010-03-25 Eagle Pharmaceuticals, Inc. Alcohol free formulation of argatroban
GB0625962D0 (en) * 2006-12-23 2007-02-07 Renovo Ltd Medicaments and methods for wound healing
CA2697160A1 (en) * 2007-08-21 2009-02-26 Harbor Biosciences, Inc. Stabilized therapeutic compositions and formulations
US8287729B2 (en) * 2008-04-28 2012-10-16 California Polytechnic Corporation Field water purification system
GB0813628D0 (en) * 2008-07-25 2008-09-03 Arrow Int Ltd Stable coated anti-cancer agent
UY33103A (es) * 2009-12-15 2011-07-29 Techsphere S A De C V Formulacion farmaceutica parenteral en suspension, de liberacion sostenida, en dosis baja y ultra baja, en terapia hormonal en el sindrome climaterico
CN106442039B (zh) 2011-06-19 2020-08-07 阿博根公司 用于样品采集的装置、溶液和方法
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
EP3936133A1 (en) 2011-11-23 2022-01-12 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
UA74095U (ru) * 2012-07-20 2012-10-10 Николай Иванович Гуменюк Препарат для лечения туберкулеза
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
WO2015042163A1 (en) * 2013-09-17 2015-03-26 Terapio Corporation Methods of preventing or treating mucositis using rlip76
CN104706578B (zh) * 2013-12-14 2019-04-23 天津金耀集团有限公司 一种醋酸甲泼尼龙混悬注射液组合物的制备方法
KR20170005819A (ko) 2014-05-22 2017-01-16 쎄러퓨틱스엠디, 인코퍼레이티드 천연 복합 호르몬 대체 제형 및 요법
US9907449B2 (en) 2015-03-16 2018-03-06 Irobot Corporation Autonomous floor cleaning with a removable pad
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017149492A1 (en) * 2016-03-02 2017-09-08 Teva Pharmaceutical Industries Ltd. Medroxyprogesterone acetate injectable compositions and methods of use
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
AU2017239645A1 (en) 2016-04-01 2018-10-18 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US11590077B2 (en) * 2016-05-06 2023-02-28 Eagle Pharmaceuticals, Inc. Fulvestrant formulations and methods of their use
JP2019516789A (ja) * 2016-05-06 2019-06-20 イーグル ファーマスーティカルズ、インク． フルベストラント配合物およびその使用方法
WO2019048906A1 (en) * 2017-09-07 2019-03-14 Teva Pharmaceutical Industries Ltd. INJECTABLE COMPOSITIONS OF MEDROXYPROGESTERONE ACETATE AND METHODS OF USE
WO2019049081A1 (en) * 2017-09-07 2019-03-14 Teva Pharmaceutical Industries Ltd. INJECTABLE COMPOSITIONS OF MEDROXYPROGESTERONE ACETATE AND METHODS OF USE
JP7220712B2 (ja) * 2017-11-08 2023-02-10 イーグル ファーマスーティカルズ、インク． フルベストラント製剤とその使用方法
BR112020013996A2 (pt) 2018-01-11 2020-12-01 Meritage Pharma, Inc. composições de cortecosteroide estáveis
US11752095B2 (en) 2018-09-07 2023-09-12 Family Health International Medroxyprogesterone acetate injectable compositions and methods of use
US10544923B1 (en) 2018-11-06 2020-01-28 Verifone, Inc. Devices and methods for optical-based tamper detection using variable light characteristics
EP3884070A4 (en) 2018-11-20 2022-09-07 Spectrum Solutions, LLC SAMPLE COLLECTION SYSTEM INCLUDING SEALING CAP AND VALVE
IT201900002857A1 (it) * 2019-02-27 2020-08-27 Ntc S R L Procedimento di riempimento di contenitori con una polvere
US11701094B2 (en) 2019-06-20 2023-07-18 Spectrum Solutions L.L.C. Sample collection system including valve and plug assemblies
KR20220140711A (ko) 2020-01-13 2022-10-18 듀렉트 코퍼레이션 불순물이 감소된 지속 방출 약물 전달 시스템 및 관련 방법
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
WO2022245939A1 (en) * 2021-05-19 2022-11-24 Acies Medical Llc Point-of-use calibration system for iron ion detection system

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2861920A (en) * 1954-05-04 1958-11-25 Upjohn Co Therapeutic suspensions of steroids containing pvp and/or pva
JPS5831210B2 (ja) * 1973-04-09 1983-07-05 武田薬品工業株式会社 アンテイナスイセイケンダクエキノセイゾウホウ
US4038389A (en) * 1975-05-07 1977-07-26 The Upjohn Company Medroxyprogesterone acetate compositions
US4154820A (en) * 1976-02-23 1979-05-15 Akzona Incorporated Compositions containing alkali metal sulfate salts of conjugated estrogens and antioxidants as stabilizers
JP2577744B2 (ja) 1986-07-18 1997-02-05 中外製薬株式会社 安定な顆粒球コロニ−刺激因子含有製剤
US5208261A (en) * 1989-12-06 1993-05-04 Akzo N.V. Stabilized solutions of psychotropic agents
ES2062310T3 (es) 1989-12-06 1994-12-16 Akzo Nv Un procedimiento para fabricar un preparado farmaceutico acuoso estabilizado.
JPH0597671A (ja) 1991-10-04 1993-04-20 Sumitomo Pharmaceut Co Ltd 注射用凍結乾燥製剤
CA2120197A1 (en) 1993-04-02 1994-10-03 Kenji Endo Stable aqueous dispersions containing liposomes
JP3862295B2 (ja) * 1993-09-30 2006-12-27 独立行政法人理化学研究所 抗肥満剤
US5540930A (en) * 1993-10-25 1996-07-30 Pharmos Corporation Suspension of loteprednol etabonate for ear, eye, or nose treatment
JP3543144B2 (ja) 1995-03-11 2004-07-14 国際試薬株式会社 臨床検査用製剤
US5780431A (en) 1996-09-20 1998-07-14 Neurobiological Technologies, Inc. Pharmaceutical formulations of corticotropin releasing factor having improved stability in liquid form
AU4344697A (en) 1996-10-04 1998-04-24 Amgen, Inc. Pharmaceutical compositions containing an mpl ligand
US5773432A (en) * 1996-10-30 1998-06-30 Schering Aktiengesellschaft Method for lowering plasma levels of lipoprotein(a)
US5880116A (en) * 1996-12-13 1999-03-09 Neurocal International Use of celastrol to treat alzheimer's disease
JP3748970B2 (ja) 1997-01-31 2006-02-22 電気化学工業株式会社 ヒアルロン酸ナトリウム含有水溶液
KR100508227B1 (ko) 1997-03-14 2006-03-23 센주 세이야꾸 가부시키가이샤 로테프레드놀에타보네이트수성현탁액
IL135186A0 (en) 1997-09-23 2001-05-20 Rentschler Biotechnologie Bmgh LIQUID INTERFERON-β FORMULATIONS
US5968918A (en) * 1997-10-17 1999-10-19 Kanda; Iwao Method for the prevention of coronary artery spasm
US5972921A (en) * 1997-12-12 1999-10-26 Hormos Medical Oy Ltd. Use of an aromatase inhibitor in the treatment of decreased androgen to estrogen ratio and detrusor urethral sphincter dyssynergia in men
WO1999051237A1 (en) 1998-04-02 1999-10-14 Akzo Nobel N.V. Oral liquid antidepressant solution
CN100389821C (zh) 1999-10-04 2008-05-28 希龙公司 稳定化的含多肽的液体药物组合物
US6495534B2 (en) * 2000-05-15 2002-12-17 Pharmacia & Upjohn Spa Stabilized aqueous suspensions for parenteral use

Also Published As

Publication number Publication date
AR029924A1 (es) 2003-07-23
EP1282402A1 (en) 2003-02-12
HK1054194B (zh) 2010-02-12
CZ303872B6 (cs) 2013-06-05
US20030114430A1 (en) 2003-06-19
CN1429101A (zh) 2003-07-09
HUP0302021A3 (en) 2011-03-28
SK15982002A3 (sk) 2003-05-02
IL152537A (en) 2007-06-17
HK1054194A1 (en) 2003-11-21
NO20025431D0 (no) 2002-11-13
NO332215B1 (no) 2012-07-30
ES2254443T3 (es) 2006-06-16
AR111695A2 (es) 2019-08-07
JP2003533467A (ja) 2003-11-11
NZ522324A (en) 2005-02-25
EA200201208A1 (ru) 2003-04-24
IL152537A0 (en) 2003-05-29
EA007682B1 (ru) 2006-12-29
DK1282402T3 (da) 2006-05-08
SI1282402T1 (sl) 2006-04-30
US20020115645A1 (en) 2002-08-22
EP1282402B1 (en) 2005-12-21
WO2001087266A1 (en) 2001-11-22
DE60116084T2 (de) 2006-08-17
CA2409059C (en) 2006-04-18
MXPA02011195A (es) 2003-03-10
AR098830A2 (es) 2016-06-15
AU6737101A (en) 2001-11-26
EE05376B1 (et) 2011-02-15
PL203075B1 (pl) 2009-08-31
IL165888A0 (en) 2006-01-15
PE20011322A1 (es) 2002-01-10
PL365793A1 (en) 2005-01-10
BR0110841A (pt) 2003-03-11
NO20025431L (no) 2003-01-13
HUP0302021A2 (hu) 2003-09-29
US6495534B2 (en) 2002-12-17
SK287641B6 (sk) 2011-05-06
KR100828957B1 (ko) 2008-05-13
JP4205341B2 (ja) 2009-01-07
CN100473376C (zh) 2009-04-01
AU2001267371B2 (en) 2006-01-05
HU229800B1 (en) 2014-07-28
ATE313316T1 (de) 2006-01-15
TWI256310B (en) 2006-06-11
IN224279B (et) 2005-02-25
ZA200208738B (en) 2003-10-29
KR20030020280A (ko) 2003-03-08
CZ20023750A3 (cs) 2003-03-12
DE60116084D1 (de) 2006-01-26
CA2409059A1 (en) 2001-11-22
US20030130245A1 (en) 2003-07-10

Similar Documents

Publication Publication Date Title
EE200200631A (et) Vesisuspensioonipõhine parenteraalne ravimpreparaat stabiliseeritud pH väärtusega ning L-metioniinikasutamine selle valmistamiseks
CR8037A (es) Derivados de 2- acilamino- 4- feniletiazol, su preparacion y su aplicacion en terapeutica
EE05387B1 (et) KinasoliiniÁderivaadid,ÁnendeÁvalmistamismeetodÁjaÁkasutamine
IL151045A0 (en) 2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors
GB2406523B (en) Improvements in and relating to the formation of knots
IL228034A0 (en) Formulations with a high concentration of antibodies and proteins
EE05516B1 (et) Indasoolid bensotiasoolid ja bensoisotiasoolid nende valmistamine ning kasutamine
AR028027A1 (es) Componente de compuestos en secciones y procedimiento para producir el mismo
NO20013332L (no) Frac-plugg med kulehylse
EP1758617A4 (en) STABLE LIQUID AND LYOPHILIZED PROTEIN FORMULATIONS
NO20025872D0 (no) Forbindelse med koniske gjenger
EE04490B1 (et) Ühend, selle valmistamise meetod ning kasutamine meditsiinis
HK1053673A1 (zh) 使蛋白不穩定的方法及其用途
HUP0300917A3 (en) Use of bradycardiac substances in the treatment of myocardial diseases associated with hypertrophy and pharmaceutical compositions containing them
AU1334602A (en) Osteopontin-coated surfaces and methods of use
NO20035581D0 (no) Farmasöytisk formulering med maskert smak samt fremstilling derav
AU2003251047A8 (en) Use of quinoline derivatives with anti-integrase effect and applications thereof
AR028198A1 (es) Variantes de pululanasa y metodos para preparar dichas variantes con propiedades predeterminadas
AU2001240025A1 (en) Cell cycle proteins associated with rad9, compositions and methods of use
EE200300044A (et) Vasoprotektiivse ja antioksüdantse toimega preparaat ning selle kasutamine
DE602005026869D1 (de) Interferonproteinmutanten und deren anwendung
EP1813671A4 (en) SOLUBLE PROTEIN AND USE THEREOF
GB0116489D0 (en) Improvements in and relating to consumption of content
GB0119497D0 (en) Expression of modified antibodies in avian cells
EP1633850A4 (en) OVR115 ANTIBODY COMPOSITIONS AND METHODS OF USE

Legal Events

Date Code Title Description
GB1A Change in the ownership or in the address of the owner